INTRODUCTION
============

A great deal of evidence indicates that endogenous creatinine clearance (C~cr~) is inadequate for measuring glomerular filtration rate (GFR) in patients with renal diseases^[@b1-kjim-8-1-28-6]--[@b8-kjim-8-1-28-6])^. C~cr~ measures GFR with a mean overestimation by 23--96%^[@b9-kjim-8-1-28-6]--[@b14-kjim-8-1-28-6])^. Furthermore, the degree of overestimation varies greatly from one patient to another and even in the same individual over time^[@b11-kjim-8-1-28-6],[@b15-kjim-8-1-28-6])^.

It has been shown that tubular secretion of creatinine increases as renal function decreases, especially in patients with glomerular disorders^[@b8-kjim-8-1-28-6]--[@b10-kjim-8-1-28-6])^. The overestimation seen in patients with renal diseases appears to be due to hypersecretion of creatinine by injured renal tubular cells^[@b11-kjim-8-1-28-6],[@b16-kjim-8-1-28-6])^. To circumvent these problems, while GFR can be measured with the aid of "true filtration markers" such as insulin, iothalamate, diethylenetriaminepenta-acetic acid and ethylenediaminetetra-acetic acid, these are less convenient in handling and more costly than creatinine.

Secretion of creatinine by the tubular transport system can be inhibited by several anionic and cationic substances^[@b17-kjim-8-1-28-6])^. Among them, cimetidine has been known to reduce secretion of creatinine without impairing GFR, improving the accuracy of C~cr~ as a marker for GFR^[@b12-kjim-8-1-28-6],[@b18-kjim-8-1-28-6],[@b19-kjim-8-1-28-6])^. However, previous studies simultaneously measured iothalamate clearance (C~10th~), as a standard GFR, and C~cr~ during cimetidine treatment. Therefore, it may have not ruled out a possible effect of cimetidine on C~10th~.

The present study was aimed to investigate the effect of cimetidine on the C~cr~. C~cr~ was measured during administration of either placebo or cimetidine. C~10th~ was simultaneously determined to serve as standard GFR.

MATERIAL AND METHODS
====================

1.. Patient Selection
---------------------

The study was performed in 25 patients with varying degrees of renal dysfunction, who were selected from inpatient population at the Division of Nephrology, Chonnam University Hospital. Informed consent was obtained from each patient. C~cr~ pre-estimated according to the Cockroft and Gault formulation^[@b20-kjim-8-1-28-6],[@b21-kjim-8-1-28-6])^ less than 10 mL/min was excluded. Other exclusion criteria were pregnancy, use of H~2~-receptor antagonist or antacids, allergy to cimetidine, use of drugs which can influence the metabolism of cimetidine or can interfere with creatinine secretion, and unstable renal function.

2.. Study Protocols
-------------------

The patients were instructed to follow a 3-day schedule to take either placebo or cimetidine. They were supine-positioned throughout and had food and fluid intake every 4 h. The amount of fluid taken was 20 mL/kg, to ensure sufficient flow of urine and to prevent tubular reabsorption of creatinine. Coffee and smoking were not permitted. They were allowed to sleep from 11 : 00 pm to 08 : 00 am.

The dose of cimetidine was adjusted according to the degree of renal dysfunction in an attempt to achieve approximately equal blood cimetidine levels ([Table 1](#t1-kjim-8-1-28-6){ref-type="table"}). To obtain maximal inhibition on the tubular creatinine secretion, the maximally permitted oral daily dose of 2,000 mg was used in case of normal renal function.

On Day 1, they were given placebos four or five times. A 24-hour urine was collected through the Foley catheter from 08 : 00 am on Day 1 to 08 : 00 am on Day 2. No clearance measurement was done. On Day 3, 24-hour urine from 08 : 00 am to 08 : 00 am on the next day was collected.

C~10th~ as standard GFR was measured between 10 : 00 am and 2 : 00 pm on Days 1 and 3 using the 24 h urine.

For the measurement of C~10th~, ^125^I-iothalamate was continuously infused (20 *μ*Ci/h, for 3 h) following a priming dose of 50 *μ*Ci as bolus. Blood samples were obtained from the arm vein opposite to that used for the iothalamate infusion at 90, 120, 150, and 180 min of infusion. Plasma creatinine or ^125^I-iothalamate concentrations at the beginning and at the end of each clearance period (30 min) were averaged. Satisfactory urinary output during these periods was maintained by replacing the urinary loss noted in the preceding clearance period with an oral load of water.

^125^I-iothalamate was counted in a gamma scintillation counter (Hewlett Packard, Cobra 5000). Creatinine concentrations were measured by a modified Jaffé reaction in an autoanalyser (Impact 400E). C~10th~ was determined by averaging values obtained from three clearance periods. The C~cr~ was computed as mL/day and converted into a mL/min.

Clearances were corrected for the body surface area. C~cr~/C~10th~ was calculated to learn to what extent C~cr~ overestimates GFR.

Whole blood counts, liver function tests and analysis of the urinary sediment were done to monitor possible side-effects of cimetidine.

Data are expressed as means±SD. To compare the renal function parameters during administration of placebo and cimetidine, paired t-test was applied. Linear regression was used to study the relation between C~cr~/C~10th~ and GFR. A P-value smaller than 0.05 was considered statistically significant.

RESULTS
=======

The subjects (12 men, 13 women) aged 41--23 years ranging between 18 and 65. Their types of renal disorders were chronic glomerulonephritis (4 cases), diabetic nephropathy (4 cases), nephrotic syndrome (3 cases), autosomal dominant polycystic kidney disease (2 cases), hypertensive nephrosclerosis (1 case), lupus nephritis(1 case), miscellaneous causes (2 cases) and unknown (4 cases).

Cimetidine had no effect on GFR measured as C~10th~, being 44±27 and 44±29 mL/min/1.73m^2^, during the placebo and during cimetidine treatment, respectively ([Table 2](#t2-kjim-8-1-28-6){ref-type="table"}). However, cimetidine resulted in a significant decrease of C~cr~, from 69±36 during the placebo to 50±31 mL/min/1.73m^2^ during the cimetidine. The difference between C~cr~ and C~10th~ decreased from 24±16 to 5±4 mL/min/1.73m^2^.

C~cr~/C~10th~ also significantly decreased from 1.72±0.51 to 1.17±0.20, indicating an improvement in validity ([Fig. 1](#f1-kjim-8-1-28-6){ref-type="fig"}). When the patients were classified into three groups, according to their renal function as measured by C~10th~, C~cr~/C~10th~ was larger in those with more severe renal dysfunction, indicating a more pronounced overestimation of GFR ([Table 3](#t3-kjim-8-1-28-6){ref-type="table"}). A significant inverse relation was noted between C~cr~/C~10th~ and GFR ([Fig. 2](#f2-kjim-8-1-28-6){ref-type="fig"}).

C~cr~ and C~10th~ disagreed during the placebo treatment, which was improved by the cimetidine treatment ([Fig. 3](#f3-kjim-8-1-28-6){ref-type="fig"}). No patient reported any side effect due to cimetidine.

DISCUSSION
==========

C~cr~ in 25 patients with renal diseases overestimated GFR by 72%, being similar to those reported in the previous studies^[@b4-kjim-8-1-28-6],[@b9-kjim-8-1-28-6])^. In addition, the degree of overestimation was larger in those with more severe renal dysfunction. A significant inverse correlation noted between C~cr~/C~10th~ and GFR, as has been shown in the previous studies^[@b1-kjim-8-1-28-6],[@b10-kjim-8-1-28-6])^, suggests that the degree of overestimation is associated with the degree of renal functional impairment.

Creatinine and cimetidine are secreted by the organic cation secretary system^[@b22-kjim-8-1-28-6])^. The reduction of tubular creatinine secretion due to cimetidine is assumed to result from competitive inhibition on the common transport system in the proximal tubule, cimetidine having a higher affinity than creatinine for the carrier at the luminal membrane^[@b23-kjim-8-1-28-6])^.

Cimetidine only incompletely reduced the tubular creatinine secretion. Previous studies^[@b19-kjim-8-1-28-6],[@b24-kjim-8-1-28-6])^ reported that patients with incomplete inhibition had a larger cimetidine clearance, along with lower plasma cimetidine concentration and cimetidine/creatinine ratio, than did those with complete inhibition^[@b19-kjim-8-1-28-6])^. This ratio is important, in that certain plasma ratio of unbound competitive compounds is necessary to induce complete inhibition^[@b25-kjim-8-1-28-6])^. Taken together, it may be recommended that a maximal permitted dose of cimetidine should be used to make the validity of C~cr~ better.

In the previous studies^[@b1-kjim-8-1-28-6],[@b12-kjim-8-1-28-6],[@b18-kjim-8-1-28-6],[@b19-kjim-8-1-28-6],[@b26-kjim-8-1-28-6],[@b27-kjim-8-1-28-6])^, C~cr~/C~10th~ after administration of cimetidine varied from 0.89 to 1.35. The variation may be related to different dosage schedules and routes of administration of cimetidine. In addition, the fall of C~cr~/C~10th~ below 1.0^[@b26-kjim-8-1-28-6])^ raises the question whether tubular reabsorption of creatinine might exist. Although tubular reabsorption of creatinine has been reported in rats^[@b28-kjim-8-1-28-6])^, evidence is lacking in humans.

On the other hand, no serious adverse effects due to cimetidine were noted, which may be of special importance where cimetidine is used for a non-therapeutic purpose. In a recent meta-analysis of randomized clinical trials with cimetidine, the adverse effect was negligible even with the dosage as high as 2,000 mg/day^[@b29-kjim-8-1-28-6])^.

The cimetidine-aided creatinine clearance can be promoted as a convenient and inexpensive as well as an exact measure of GFR. It may replace classical measurement of GFR with a true filtration marker as this is more expensive and less convenient, especially for the long-term follow-up studies of renal function^[@b30-kjim-8-1-28-6])^. Moreover, monitoring the progress of renal deterioration by plotting the reciprocal values of serum creatinine against time^[@b31-kjim-8-1-28-6])^ might become more reliable by the use of cimetidine. Finally, cimetidine may improve the sensitivity of serum creatinine in detecting minimal changes in renal function by restoring the inverse relationship between serum creatinine and GFR, which is actually blunted by the increase of tubular secretion and reduction of GFR^[@b1-kjim-8-1-28-6])^.

In summary, our results show that oral administration of cimetidine improves the accuracy of C~cr~ as a marker for GFR.
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###### 

Daily Doses of Cimetidine for Different Levels of Renal Function

  C~cr~*[^a^](#tfn1-kjim-8-1-28-6){ref-type="table-fn"}* (mL/min /1.73 m^2^)   Doses on Days 2 and 3*[^b^](#tfn2-kjim-8-1-28-6){ref-type="table-fn"}* (mg)   Last morning dose (mg)
  ---------------------------------------------------------------------------- ----------------------------------------------------------------------------- ------------------------
  \>75                                                                         400--400--400--800                                                            800
  50∼75                                                                        400--400--400--400                                                            600
  30∼50                                                                        400--400--600                                                                 600
  20∼30                                                                        400--400--400                                                                 400

C~cr~, endogenous creatinine clearance pre-estimated according to the Cockroft-Gault equation.

The first dose was given on waking up, the last dose at bedtime, and interjacent 2--3 doses at regular intervals.

###### 

Creatinine Clearance (C~cr~), Iothalamate Clearance (C~10th~) and Ratio of C~cr~ to C~10th~ During Placebo and Cimetidine Administration

  Patient             Placebo   C~cr~/C~10th~                                                           Cimetidine   C~cr~/C~10th~
  ----------- ------- --------- --------------- ------------------------------------------------------- ------------ -----------------------------------------------------------
  1           92      74        1.23            75                                                      73           1.03
  2           89      68        1.30            74                                                      71           1.04
  3           32      22        1.44            25                                                      24           1.07
  4           27      11        2.46            16                                                      9            1.87
  5           33      19        1.80            20                                                      19           1.10
  6           47      37        1.28            40                                                      36           1.10
  7           57      32        1.77            38                                                      35           1.07
  8           124     93        1.35            120                                                     104          1.15
  9           44      33        1.31            38                                                      34           1.11
  10          55      39        1.42            46                                                      41           1.12
  11          129     84        1.54            87                                                      82           1.05
  12          27      14        1.95            11                                                      12           0.97
  13          51      27        1.92            33                                                      20           1.65
  14          158     124       1.27            138                                                     125          1.10
  15          36      28        1.32            33                                                      29           1.13
  16          86      55        1.57            65                                                      57           1.13
  17          63      42        1.50            38                                                      39           0.96
  18          34      13        2.63            20                                                      16           1.23
  19          129     49        2.65            54                                                      43           1.27
  20          63      55        1.14            57                                                      52           1.09
  21          62      43        1.43            47                                                      39           1.21
  22          44      19        2.27            23                                                      17           1.34
  23          78      33        2.32            47                                                      37           1.26
  24          88      32        2.78            38                                                      31           1.22
  25          70      49        1.42            58                                                      55           1.05
  (mean±SD)   69±36   44±27     1.72±0.51       50±31[^\*^](#tfn3-kjim-8-1-28-6){ref-type="table-fn"}   44±29        1.17±0.20[^\*^](#tfn3-kjim-8-1-28-6){ref-type="table-fn"}

p\<0.001, compared with placebo.

###### 

C~cr~/C~10th~ at Various Levels of Renai Function during Placebo and Cimetidine Administration

               C~10th~(mL/min/1.73 m^2^)                                                                                                 
  ------------ ------------------------------------------------------------- ----------------------------------------------------------- -----------------------------------------------------------
  Placebo      1.91±0.52                                                     1.53±0.47                                                   1.38±0.14
  Cimetidine   1.22±0.25[^\*\*^](#tfn6-kjim-8-1-28-6){ref-type="table-fn"}   1.09±0.10[^\*^](#tfn5-kjim-8-1-28-6){ref-type="table-fn"}   1.10±0.04[^\*^](#tfn5-kjim-8-1-28-6){ref-type="table-fn"}

Abbreviations as in [Table 1](#t1-kjim-8-1-28-6){ref-type="table"}.

p\<0.01,

p\<0.001: compared with placebo.
